Following the May meetings of GMMMG and CEGC, the following actions have been published to the GMMMG website. This includes the recommendations made by GMMMG in May 2025 and NICE Technology appraisals published in January 2025. A summary of approved decisions can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Updates to formulary and RAG list
- vamorolone for Duchenne muscular dystrophy – RED
- vadadustat for symptomatic anaemia in CKD – RED
Available at https://www.greatermanchesterformulary.nhs.uk/. Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Pathways and guidelines
New and updated pathways and commissioning statements:
- Tirzepatide commissioning statement – https://gmmmg.nhs.uk/guidance/medicine-and-device-recommendations/
- Frequently asked questions on implementation of the New Topiramate Safety Measures in Greater Manchester – https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/
Colleagues are asked to disseminate for implementation within your organisations.
All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.